Business Context and Reporting Period
Company: iBioPharma, Inc. (formerly InB:Biotechnologies, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: A biotechnology company focused on a proprietary plant-based expression platform for producing vaccines, antibodies, and therapeutic proteins. The company also utilizes plants for high-quality nutritional supplements. Following a spin-off from Integrated BioPharma, Inc. in August 2008, the company operates as an independent public entity.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2009 | Nine Months Ended Mar 31, 2009 |
|---|---|---|
| Net Sales | $326,900 | $1,039,400 |
| Cost of Sales | $166,400 | $497,100 |
| Gross Margin | 49% | 52% |
| Research & Development Costs | $83,100 | $714,300 |
| Selling & Administrative Expenses | $405,100 | $1,276,900 |
| Net Loss | Not explicitly stated in text | Not explicitly stated in text |
| Cash Used in Operating Activities | Not explicitly stated | $1,828,000 |
| Working Capital | $1,299,000 (as of Mar 31, 2009) | |
| Cash Balance | Approx. $1.4 million (on deposit with JP Morgan Chase) |
Material Changes vs. Prior Period
- Revenue: Net sales decreased 21% ($87,100) for the three months ended March 31, 2009, compared to the prior year. However, for the nine-month period, sales increased 17% ($150,400) compared to the prior year.
- Customer Concentration: Sales reliance shifted. In the three months ended March 31, 2009, 58% of sales came from Natural Alternatives International (via Mannatech) and 44% from FhCMB (via DARPA grant). In the prior year, sales were heavily concentrated with L. Perrigo Company and Natural Alternatives International.
- R&D Expenses: R&D costs decreased significantly in the three-month period ($83,100 vs. $257,200) due to the suspension of seasonal flu vaccine work in favor of pandemic flu trials funded by the Bill & Melinda Gates Foundation. For the nine-month period, R&D increased to $714,300 due to milestone payments and increased salaries.
- Corporate Support Charges: Charges from the former parent, Integrated BioPharma, dropped to zero for the three months ended March 31, 2009, following the August 2008 spin-off. A transitional services agreement now charges approximately $75,000 over nine months.
- Liquidity: Working capital improved from a negative $1,761,000 as of June 30, 2008, to a positive $1,299,000 as of March 31, 2009, driven by a $5.0 million private placement in August 2008.
Guidance, Outlook, and Risks
- Capital Runway: Proceeds from the August 2008 private placement ($4.6 million net) are expected to cover anticipated costs through the first quarter of calendar year 2010. The company warns that failure to raise additional capital by then could force a suspension of operations.
- Strategic Shift: The company suspended preparation for clinical trials of a seasonal flu vaccine in January 2009 to focus on a pandemic flu vaccine candidate, which is being funded by an $8.7 million grant from the Bill & Melinda Gates Foundation to FhCMB.
- Future Commitments: The company has committed to non-refundable payments of $2.0 million per year for five years (starting November 2009) to FhCMB for research and development, totaling $10.0 million.
- Risks:
- Financing: Inability to obtain financing on favorable terms post-spin-off could restrict operations.
- Customer Concentration: Loss of major customers (Natural Alternatives International, FhCMB, L. Perrigo) would adversely affect sales.
- Economic Conditions: Current economic conditions may reduce business and consumer spending, impacting performance.
- Subsequent Event: On April 1, 2009, the company granted an exclusive license to IHT Health Products, Inc. (a subsidiary of the former parent) for its patented nutritional process in exchange for a 5% royalty on net sales.
Investor Verification Checklist
- Cash Burn Rate: Verify the specific monthly cash burn rate to confirm if the $1.4 million cash balance will indeed last until Q1 2010 as projected.
- Grant Dependency: Assess the stability of the $8.7 million Gates Foundation grant funding the pandemic flu vaccine trials and the terms of the subcontract with FhCMB.
- Future Obligations: Confirm the company's ability to meet the $10.0 million commitment to FhCMB starting in November 2009 without additional equity dilution or debt.
- Customer Contracts: Review the terms and duration of the supply agreements with Mannatech/Natural Alternatives International and the DARPA subcontract with FhCMB.
- Related Party Transactions: Scrutinize the new exclusive license agreement with IHT Health Products, Inc. and the transitional services fees paid to the former parent.